Published in Malar J on July 01, 2011
Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malar J (2012) 1.11
The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics. Br J Clin Pharmacol (2012) 1.07
Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria. Malar J (2012) 0.99
A robust design for identification of the Parasite Clearance Estimator. Malar J (2013) 0.87
Statistical power calculations for mixed pharmacokinetic study designs using a population approach. AAPS J (2014) 0.83
Optimizing drug development of anti-cancer drugs in children using modelling and simulation. Br J Clin Pharmacol (2013) 0.81
Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges. Br J Clin Pharmacol (2015) 0.79
An investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat. Malar J (2012) 0.78
Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs. AAPS J (2014) 0.77
Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. Br J Clin Pharmacol (2014) 0.76
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
A research agenda to underpin malaria eradication. PLoS Med (2011) 5.34
Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J (2009) 2.70
Antimalarial dosing regimens and drug resistance. Trends Parasitol (2008) 2.40
Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther (2006) 2.18
Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab Dispos (2002) 1.70
Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol (2006) 1.64
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed (2001) 1.57
Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth (2004) 1.53
A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.50
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med (2006) 1.42
World Antimalarial Resistance Network (WARN) IV: clinical pharmacology. Malar J (2007) 1.38
Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J (2009) 1.26
Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs (2000) 1.19
Pharmacokinetics of two paediatric artesunate mefloquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon. J Antimicrob Chemother (2007) 1.12
Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malar J (2011) 1.02
Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci (2000) 1.01
Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. J Pharmacokinet Pharmacodyn (2005) 0.98
Methods of robust design of nonlinear models with an application to pharmacokinetics. J Biopharm Stat (2010) 0.93
Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection. Br J Clin Pharmacol (2008) 0.91
Towards optimal design of anti-malarial pharmacokinetic studies. Malar J (2009) 0.85
Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. Eur J Clin Pharmacol (2009) 0.82
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Typhoid fever. N Engl J Med (2002) 12.96
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet (2012) 11.82
Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA (2010) 11.59
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med (2004) 10.14
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (2010) 8.52
Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med (2005) 8.36
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis (2012) 6.94
Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol (2006) 6.34
A major genome region underlying artemisinin resistance in malaria. Science (2012) 6.25
Mixed-species malaria infections in humans. Trends Parasitol (2004) 6.01
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One (2009) 5.81
Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J (2011) 5.65
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med (2005) 4.65
Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg (2007) 4.58
Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (2010) 4.50
Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med (2005) 4.47
Manslaughter by fake artesunate in Asia--will Africa be next? PLoS Med (2006) 4.46
Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health (2006) 4.44
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis (2007) 4.35
Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J (2008) 4.33
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J (2009) 4.25
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis (2006) 4.14
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet (2004) 4.14
Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A (2012) 4.10
Early origin and recent expansion of Plasmodium falciparum. Science (2003) 4.07
Counterfeit anti-infective drugs. Lancet Infect Dis (2006) 3.91
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet (2006) 3.90
Rickettsial infections and fever, Vientiane, Laos. Emerg Infect Dis (2006) 3.87
High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis (2010) 3.81
Impact of tobacco control policies and mass media campaigns on monthly adult smoking prevalence. Am J Public Health (2008) 3.72
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet (2004) 3.72
A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. Mol Biol Evol (2003) 3.67
Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One (2013) 3.66
Quantification of lean bodyweight. Clin Pharmacokinet (2005) 3.59
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis (2002) 3.46
Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis (2010) 3.21
The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med (2005) 3.15
A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis (2005) 3.15
In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J (2012) 3.13
Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med (2007) 3.13
How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health (2007) 3.13
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis (2010) 3.08
The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis (2008) 3.05
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. BMJ (2003) 3.05
How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health (2005) 2.95
Spurious amplification of a Plasmodium vivax small-subunit RNA gene by use of primers currently used to detect P. knowlesi. J Clin Microbiol (2009) 2.85
Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis (2004) 2.82
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A (2008) 2.80
Central role of the spleen in malaria parasite clearance. J Infect Dis (2002) 2.80
In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother (2004) 2.77
Antimalarial drug toxicity: a review. Drug Saf (2004) 2.76
Alcohol consumption and cardiovascular mortality accounting for possible misclassification of intake: 11-year follow-up of the Melbourne Collaborative Cohort Study. Addiction (2007) 2.72
Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother (2010) 2.68
Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated. PLoS Negl Trop Dis (2010) 2.68
Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med (2006) 2.65
A dominant clone of Leptospira interrogans associated with an outbreak of human leptospirosis in Thailand. PLoS Negl Trop Dis (2007) 2.65
The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med (2010) 2.61
Counterfeit artesunate antimalarials in southeast Asia. Lancet (2003) 2.59
Editorial: clinical trials in tropical diseases: a politically incorrect view. Trop Med Int Health (2006) 2.59
Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electron-microscopic pathology. Acta Trop (2004) 2.58
Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infect Dis (2012) 2.58
Short communication: An assessment of the use of malaria rapid tests by village health volunteers in rural Laos. Trop Med Int Health (2004) 2.56
Murder by fake drugs. BMJ (2002) 2.54
Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics (2011) 2.53
New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women. J Infect Dis (2012) 2.52
Artemisinin-based combinations. Curr Opin Infect Dis (2005) 2.51
Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet (2010) 2.48
An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.47
Contrasting genetic structure in Plasmodium vivax populations from Asia and South America. Int J Parasitol (2007) 2.41
Antimalarial dosing regimens and drug resistance. Trends Parasitol (2008) 2.40
Stage-dependent production and release of histidine-rich protein 2 by Plasmodium falciparum. Trans R Soc Trop Med Hyg (2005) 2.38
The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. J Infect Dis (2005) 2.38
Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med (2009) 2.36
Nonrandom distribution of Burkholderia pseudomallei clones in relation to geographical location and virulence. J Clin Microbiol (2006) 2.34
The transcriptome of Plasmodium vivax reveals divergence and diversity of transcriptional regulation in malaria parasites. Proc Natl Acad Sci U S A (2008) 2.33
Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother (2002) 2.32
The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmission. Am J Trop Med Hyg (2004) 2.32
Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis (2005) 2.29
Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother (2003) 2.26
Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis (2010) 2.24
Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS One (2011) 2.24
The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci (2002) 2.20
Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J (2006) 2.19
Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther (2006) 2.18
Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother (2004) 2.17